398P - Lapatinib and capecitabine in the treatment of HER2-positive breast cancer with brain metastases

Date 27 September 2014
Event ESMO 2014
Session Poster Display session
Topics Anticancer Agents
Breast Cancer
Biological Therapy
Presenter Roman Dubianski
Citation Annals of Oncology (2014) 25 (suppl_4): iv116-iv136. 10.1093/annonc/mdu329
Authors R. Dubianski1, E. Brewczynska2, I. Lemanska2, E. Szombara3, Z. Nowecki4
  • 1Breast Cancer Clinic, MSC Memorial Cancer Centre and Institute Maria Sklodowska-Curie, 02-781 - Warsaw/PL
  • 2Department Of Breast Cancer And Reconstructive Surgery, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw/PL
  • 3Medical Oncology, Marie Curie Oncology Center, Warsaw/PL
  • 4Deptartment Of Gastrointestinal Cancer, Maria Sklodowska-Curie Memorial Cancer Center, 02-781 - Warsaw/PL



Brain metastases (BM) are a common clinical problem in patients with HER2-positive metastatic breast cancer. The retrospective study was designed to evaluate the efficacy of lapatinib and capecitabine in this group of advanced breast cancer patients.


Group of 83 patients with HER-2 positive metastatic breast cancer receiving lapatinib and capecitabine between July 2007 and May 2013 was retrospectivelly evaluated. Patients received lapatinib 1250 mg once daily and capecitabine 2000 mg/m(2) daily in two doses, days 1-14, every 21 days. All patients were treated with trastuzumab either in adjuvant or metastatic setting and most of the patients (90%) received prior therapy for metastatic disease. Patients were assessed for median time to progression (mTTP) and toxicity of treatment.


Among 83 patients 19 (23%) had brain metastases. Median time to progression was 35 weeks in patients with BM and 28 weeks in patients without BM (P = 0.028). Among adverse events the most common were hand-foot syndrome (59% of patients) and diarrhoea (42%). All toxicities were well manageable.


Lapatinib plus capecitabine is effective and well tolerated treatment in breast cancer patients with brain metastases.


All authors have declared no conflicts of interest.